NEW YORK (GenomeWeb News) – Investment bank ISI Group this week downgraded shares of PerkinElmer and upgraded shares of Danaher.

In a research note, analyst Ross Muken lowered the rating for PerkinElmer to Neutral from Buy, saying that the company's stock is "now approaching the upper end of its historical range, and therefore we see limited opportunity for multiple expansion." He maintained a $49 price target on PerkinElmer's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.